Monday, July 13, 2026
🇺🇸 FDA

Intelligence · Clinical Development

Clinical Development Intelligence

Pipeline intelligence, regulatory progress, and competitive landscape — not a flat database. Track phase distribution, catalysts, and sponsor rankings across indexed programs.

Programs indexed 20,548
Sponsors 1,771
Drugs tracked 4,798

Quick answer

NovaPharmaNews Clinical Development Intelligence tracks 20,548 pharmaceutical pipeline programs from ClinicalTrials.gov with phase distribution, therapeutic area hubs, NDA/BLA watchlists, upcoming readouts, company rankings, and competitive landscape views — designed for BD, investor, and regulatory teams benchmarking against Evaluate Pharma, Citeline, and GlobalData.

Search pipeline intelligence

P0 · Clinical development dashboard

Pipeline intelligence at a glance

Real-time view of clinical development activity across 20,548 indexed programs — phase distribution, therapeutic area density, and the most active sponsors. Benchmarked against Evaluate Pharma, Citeline, and GlobalData pipeline coverage models.

Total programs 20,548 ClinicalTrials.gov index Phase III+ 7,266 Late-stage & filed NDA / BLA 0 Regulatory filings
Active trials 10,940 Recruiting / active status
Dated catalysts 0 Expected milestones

7,266 Phase III+ assets

Late-stage clinical development spanning pivotal trials through approval.

Oncology leads pipeline density

5,539 programs indexed — highest therapeutic area concentration.
P0 · Pipeline stage distribution

Development stage breakdown

Where clinical assets sit across the development continuum — click a stage to browse the full hub.

Phase II 7,238
Phase III 5,427
Phase I 4,713
Approved 1,839
Browse Phase III hub →
P0 · Most active companies

Top pipeline sponsors

Sponsors ranked by indexed program count — each links to a dedicated company pipeline hub.

  1. 1
    Chinese Academy of

    189 late-stage programs in registrational or filing phase.

    1,328
  2. 2
    Takeda

    393 late-stage programs in registrational or filing phase.

    1,179
  3. 3
    First People's Hospital

    117 late-stage programs in registrational or filing phase.

    1,136
  4. 4
    BRIGHT MINDS BIOSCIENCES

    139 late-stage programs in registrational or filing phase.

    1,063
  5. 5
    United Therapeutics Europe

    199 late-stage programs in registrational or filing phase.

    1,032
  6. 6
    Anaxis Pharma

    198 late-stage programs in registrational or filing phase.

    642
  7. 7
    Regeneron UK

    129 late-stage programs in registrational or filing phase.

    493
  8. 8
    Teva Pharma

    148 late-stage programs in registrational or filing phase.

    473
Full company directory →
P0 · Therapeutic area overview

Pipeline density by therapeutic area

Sector hubs for oncology, metabolic, CNS, autoimmune, rare disease, and infectious disease — cross-linked to drug therapeutic area pages where available.

5,539 Oncology 5,539 programs with oncology indications. 1,112 Infectious disease 1,112 programs with infectious disease indications. 985 Autoimmune & immunology 985 programs with autoimmune & immunology indications. 744 Metabolic & obesity 744 programs with metabolic & obesity indications. 675 Neurology & CNS 675 programs with neurology & cns indications. 19 Rare disease 19 programs with rare disease indications.
P1 · Upcoming readouts

Clinical catalyst calendar

Programs with expected next milestones from ClinicalTrials.gov — data readouts, interim analyses, and trial completions. Comparable to Citeline Trialtrove catalyst tracking and BioCentury pipeline calendars.

No programs in this view yet.

Congress readout calendar →
P1 · NDA / BLA watchlist

Regulatory submissions in flight

Programs at filing stage — monitor agency review timelines, PDUFA dates, and CHMP opinions. Endpoints News and Evaluate Pharma regulatory trackers cover similar late-stage assets.

No programs in this view yet.

Full NDA/BLA hub →
P1 · Recently approved programs

Latest approvals & launches

Programs marked approved or launched in registry data — cross-link to sponsor pipeline hubs and drug profiles.

  1. Algorithm TreatmentApproved

    BRIGHT MINDS BIOSCIENCES · small molecule · 1 trial · May 22, 2026

    Program marked approved or launched in registry data.

  2. DeutetrabenazineApproved

    Teva Pharma · small molecule · 1 trial · May 22, 2026

    Program marked approved or launched in registry data.

  3. Shenfu InjectionApproved

    First People's Hospital · small molecule · 2 trials · May 22, 2026

    Program marked approved or launched in registry data.

  4. Lecanemab 10 mg/kgApproved

    First People's Hospital · small molecule · 1 trial · May 22, 2026

    Program marked approved or launched in registry data.

  5. DupilumabApproved

    Regeneron UK · small molecule · 13 trials · May 22, 2026

    Program marked approved or launched in registry data.

  6. Athena strategyApproved

    BRIGHT MINDS BIOSCIENCES · other · 1 trial · May 20, 2026

    Program marked approved or launched in registry data.

  7. FruquintinibApproved

    Takeda · small molecule · 1 trial · May 20, 2026

    Program marked approved or launched in registry data.

  8. DupilumabApproved

    Regeneron UK · small molecule · 1 trial · May 20, 2026

    Program marked approved or launched in registry data.

Approved programs hub →
P1 · Fast track programs

Expedited development watchlist

Orphan, breakthrough, and fast track signals inferred from milestone text and linked drug regulatory profiles — IQVIA and GlobalData flag similar accelerated pathways.

  1. Loncastuximab TesirinePhase III

    ADC Therapeutics · small molecule · 1 trial

    Expedited development signal — orphan, breakthrough, or fast track designation inferred from registry or linked drug profile.

  2. OlezarsenPhase III

    IONIS PHARMACEUTICALS · small molecule · 2 trials

    Expedited development signal — orphan, breakthrough, or fast track designation inferred from registry or linked drug profile.

  3. PegcetacoplanPhase III

    Genzyme Europe · small molecule · 3 trials

    Expedited development signal — orphan, breakthrough, or fast track designation inferred from registry or linked drug profile.

  4. PegcetacoplanPhase III

    Genzyme Europe · small molecule · 2 trials

    Expedited development signal — orphan, breakthrough, or fast track designation inferred from registry or linked drug profile.

  5. PegcetacoplanPhase III

    Genzyme Europe · small molecule · 1 trial

    Expedited development signal — orphan, breakthrough, or fast track designation inferred from registry or linked drug profile.

  6. AXS-05 (dextromethorphan-bupropion)Phase III

    Axsome Therapeutics · small molecule · 2 trials

    Expedited development signal — orphan, breakthrough, or fast track designation inferred from registry or linked drug profile.

  7. OlezarsenPhase III

    IONIS PHARMACEUTICALS · small molecule · 3 trials

    Expedited development signal — orphan, breakthrough, or fast track designation inferred from registry or linked drug profile.

  8. APL-2, PegcetacoplanPhase III

    Genzyme Europe · small molecule · 1 trial

    Expedited development signal — orphan, breakthrough, or fast track designation inferred from registry or linked drug profile.

Rare disease pipeline →
P2 · Competitive landscape

Therapeutic area competition map

Top sponsors per therapeutic area — understand who dominates oncology, metabolic, CNS, and other sectors. Mirrors Evaluate Pharma competitive landscape views and Citeline sponsor rankings.

P2 · Company pipeline rankings

Global sponsor leaderboard

Ranked by total indexed programs with late-stage counts — each row links to a company pipeline hub for full program lists.

  1. 1
    Chinese Academy of

    189 late-stage programs in registrational or filing phase.

    1,328
  2. 2
    Takeda

    393 late-stage programs in registrational or filing phase.

    1,179
  3. 3
    First People's Hospital

    117 late-stage programs in registrational or filing phase.

    1,136
  4. 4
    BRIGHT MINDS BIOSCIENCES

    139 late-stage programs in registrational or filing phase.

    1,063
  5. 5
    United Therapeutics Europe

    199 late-stage programs in registrational or filing phase.

    1,032
  6. 6
    Anaxis Pharma

    198 late-stage programs in registrational or filing phase.

    642
  7. 7
    Regeneron UK

    129 late-stage programs in registrational or filing phase.

    493
  8. 8
    Teva Pharma

    148 late-stage programs in registrational or filing phase.

    473
  9. 9
    George Institute for

    94 late-stage programs in registrational or filing phase.

    406
  10. 10
    Novartis India

    145 late-stage programs in registrational or filing phase.

    341
  11. 11
    Hospital Authority

    61 late-stage programs in registrational or filing phase.

    322
  12. 12
    Disc Medicine

    59 late-stage programs in registrational or filing phase.

    308
P2 · Regulatory catalysts

Near-term regulatory events

Active filings plus Phase III programs with milestones within 180 days — the regulatory progress layer for BD and investor teams.

No programs in this view yet.

FDA submission types guide →
P2 · Disease opportunity maps

Indication clusters by program density

Top indication clusters ranked by sponsor count and late-stage density — white-space and crowded-market signals until dedicated disease hubs launch.

healthy 424 programs · 89 sponsors · 3 late-stage 89 sponsors · 3 late-stage programs. healthy-volunteers 291 programs · 88 sponsors · 5 late-stage 88 sponsors · 5 late-stage programs. non-small-cell-lung-cancer 186 programs · 70 sponsors · 66 late-stage 70 sponsors · 66 late-stage programs. breast-cancer 160 programs · 72 sponsors · 45 late-stage 72 sponsors · 45 late-stage programs. asthma 159 programs · 37 sponsors · 62 late-stage 37 sponsors · 62 late-stage programs. multiple-myeloma 127 programs · 49 sponsors · 29 late-stage 49 sponsors · 29 late-stage programs. covid-19 99 programs · 41 sponsors · 27 late-stage 41 sponsors · 27 late-stage programs. acute-myeloid-leukemia 98 programs · 45 sponsors · 20 late-stage 45 sponsors · 20 late-stage programs. advanced-solid-tumors 98 programs · 51 sponsors 51 sponsors competing across 98 indexed programs. rheumatoid-arthritis 96 programs · 49 sponsors · 25 late-stage 49 sponsors · 25 late-stage programs. prostate-cancer 96 programs · 40 sponsors · 24 late-stage 40 sponsors · 24 late-stage programs. schizophrenia 78 programs · 30 sponsors · 27 late-stage 30 sponsors · 27 late-stage programs.
P3 · Personalized watchlists

Follow programs, companies & diseases

Build a pipeline intelligence feed — milestone alerts, regulatory filings, and competitive moves. No account required; uses the same subscription infrastructure as our events hub.

Follow company

Alerts when new programs publish or milestones update.

Follow program

Track a specific clinical development asset.

Follow disease

Indication-level competitive intelligence digest.

Follow therapeutic area

Sector-wide pipeline density and catalyst alerts.

View your intelligence feed · Weekly pipeline digest · Data sources

Latest indexed programs

Recent programs from the index — each links to a sponsor program profile with hub cross-links. Browse Phase III hub

  1. Baricitinib

    Eli Lilly and Company

    Systemic Lupus Erythematosus

    phase 3 small molecule terminated

    1 trial

  2. Barley beta-glucan(3.0g)

    Hospital Authority, Hong Kong

    Overweight; Hyperlipidemia

    phase 3 other completed

    1 trial

  3. Bavencio 20 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Solid Tumors

    phase 3 small molecule active

    1 trial

  4. BaxHTN / D6970C00002

    AstraZeneca AB

    Uncontrolled hypertension (uTHN) defined as blood pressure that remains higher than goal levels despite patients being treated with 2 anti-hypertensive agents, including a diuretic. Resistant hypertension (rHTN) defined as blood pressure that remains higher than goal levels despite the use of at least 3 anti hypertensive drugs of different classes at maximum tolerated dose, including a diuretic.

    phase 3 small molecule active

    1 trial

  5. Baxdrostat

    AstraZeneca

    Primary Hyperaldosteronism

    phase 3 small molecule active

    1 trial

  6. Baxdrostat

    AstraZeneca

    Uncontrolled Hypertension

    phase 3 small molecule completed

    2 trials

  7. Baxdrostat, Baxdrostat Placebo

    AstraZeneca AB

    Resistant hypertension (rHTN) defined as blood pressure that remains higher than goal levels despite the use of at least 3 anti hypertensive drugs of different classes at maximum tolerated dose, including a diuretic.

    phase 3 small molecule active

    1 trial

  8. Beclomethasone Dipropionate 640

    Teva Pharma GmbH

    Persistent Asthma

    phase 3 small molecule completed

    1 trial

  9. Beclomethasone dipropionate

    Teva Pharma GmbH

    Seasonal Allergic Rhinitis

    phase 3 small molecule completed

    1 trial

  10. Beclomethasone dipropionate

    Teva Pharma GmbH

    Rhinitis, Allergic, Perennial

    phase 3 small molecule completed

    1 trial

  11. Beclomethasone dipropionate

    Teva Pharma GmbH

    Asthma

    phase 3 small molecule completed

    2 trials

  12. Beclomethasone dipropionate BAI

    Teva Pharma GmbH

    Asthma

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.